High-Dose Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC with Meningeal Symptoms as the First Symptom

被引：0
|
作者：
Wang, W. [1 ,2 ]
Fan, S. B. [1 ]
Huang, X. P. [1 ]
Zhong, M. X. [1 ]
Guo, J. [1 ]
机构：
[1] Chongqing Univ Three Gorges Hosp, Ctr Canc, Chongqing, Peoples R China
[2] Chongqing Municipal Clin Res Ctr Geriatr Dis, Chongqing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
aumolertinib; intrathecal chemotherapy; leptomeningeal metastasis;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-24
引用
收藏
页码：S650 / S650
页数：1
相关论文
共 50 条
  • [1] High-Dose Aumolertinib Combined Intrathecal Chemotherapy for the Treatment of EGFR-Mutated NSCLC with Leptomeningeal Metastasis
    Wang, W.
    Zhong, M.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S625 - S626
  • [2] Aumolertinib Combined with Carbamazepine and Intrathecal Pemetrexed for EGFR-mutated LM NSCLC with Symptomatic Epilepsy
    Li, L.
    Yang, M.
    Huang, D. Y.
    Liu, F.
    Zhang, L.
    Song, X. W.
    Lv, Y. J.
    Teng, C.
    Fan, C. J.
    Tian, D.
    Shen, W. X.
    Jiang, Q. Y.
    Lu, D.
    Xin, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S351 - S351
  • [3] Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles
    Wang, W.
    Fan, S. B.
    Huang, X. P.
    Zhong, M. X.
    Guo, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S338 - S338
  • [4] Case report: A case report and literature review on the efficacy of high-dose aumolertinib combined intrathecal pemetrexed by Ommaya reservoir for EGFR-mutated NSCLC with leptomeningeal metastasis as the initial symptoms
    Zhong, Maoxi
    Zhou, Li
    Guo, Jing
    Chen, Chuan
    Wang, Wei
    Huang, Xiaoping
    Liu, Yi
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [5] Efficacy and safety of high dose furmonertinib combined with intrathecal injection in EGFR-mutated advanced NSCLC patients with LM progressed on osimertinib
    Li, X.
    Zheng, X.
    An, J.
    Hua, Y.
    Ding, X.
    Shi, H.
    Xu, W.
    Li, Y.
    Zhou, L.
    ANNALS OF ONCOLOGY, 2023, 34
  • [6] High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC
    Fan, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S422 - S422
  • [7] Aumolertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage I NSCLC with Multiple High-Risk Factors
    Wu, Q.
    Ni, M.
    Xue, F.
    Wu, X.
    Jiang, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S545 - S545
  • [8] High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study
    Chen, Haiyang
    Yang, Sen
    Wang, Lili
    Wu, Yingxi
    Wu, Yufeng
    Ma, Shuxiang
    He, Zhen
    Zhang, Cuicui
    Liu, Yang
    Tang, Haoran
    Dong, Hang
    Wang, Qiming
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (01) : 65 - 75
  • [9] High-dose almonertinib in treatment-naive EGFR-mutated NSCLC with CNS metastases: Efficacy and biomarker analysis.
    Fan, Yun
    Li, Hui
    Xu, Yanjun
    Huang, Zhiyu
    Qin, Jing
    Zhou, Rongrong
    He, Jing-Dong
    Zhu, Junfei
    Yu, Sz
    Chen, Kaiyan
    Han, Guang
    Chen, Jun
    Tan, Wei
    Gong, Lei
    Lou, Guangyuan
    Ren, Biyong
    Chen, Xiangqi
    Zhang, Dianbao
    Lu, Hongyang
    Hong, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] High-dose aumolertinib in EGFR-mutant NSCLC patients with brain metastases: Primary data from ACHIEVE
    Fan, Y.
    Zhu, J.
    He, J.
    Zhou, R.
    Chen, J.
    Han, G.
    Ren, B. Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1585 - S1585
12345